The week in pharma: action, reaction and insight – week to February 4, 2022

6 February 2022

Among last week’s notable news, Pfizer and Ionis pulled the plug on the development of their cholesterol candidate vupanorsen, with rights to the drug returned to Ionis. US biotech Biogen last week exercised its option to co-develop cancer candidate mosunetuzumab, paying Roche a one-time fee of $30 million to do so. Separately, Biogen also released financial results for 2021, along with business development plans as it tries to overcome the disappointment of its Alzheimer’s treatment Aduhelm. Also, cell therapy developer Orchard Therapeutics gained clearance in England and Wales for its gene therapy Libmeldy for a rare disease affecting babies, which at a list price of around $3.8 million is seen as the most expensive drug in the world, although this has been heavily discounted.

Vupanorsen discontinuation impact for Ionis' pipeline, raises questions on ANGPTL3

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK